排序方式: 共有26条查询结果,搜索用时 15 毫秒
11.
Eirini Katodritou Evangelos Terpos Efstathios Kastritis Sossana Delimpasis Argiris S. Symeonidis Panagiotis Repousis Marie-Christine Kyrtsonis Chrysa Vadikolia Eurydiki Michalis Genovefa Polychronidou Michael Michael Sofia Papadaki Maria Papathanasiou Kyriaki Kokoviadou Anna Kioumi Eythimia Vlachaki Christina Hadjiaggelidou Alexandra Kouraklis Ioannis Patsias Maria Gavriatopoulou Maria Kotsopoulou Evgenia Verrou Vasiliki Gastari Dimitrios Christoulas Evlambia Giannopoulou Anastasia Pouli Pavlina Konstantinidou Achilles Anagnostopoulos Meletios-Athanasios Dimopoulos 《Annals of hematology》2015,94(12):2033-2042
12.
Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies 下载免费PDF全文
Flora Zagouri Efstathios Kastritis Athanasios Zomas Evangelos Terpos Eirini Katodritou Argiris Symeonidis Sosana Delimpasi Anastasia Pouli Theodoros P. Vassilakopoulos Eurydiki Michalis Stavroula Giannouli Zafiris Kartasis Anna Christoforidou Kiriaki Kokoviadou Eleftheria Hatzimichael Dimitra Gika Catherine Megalakaki Maria Papaioannou Marie‐Christine Kyrtsonis Kostas Konstantopoulos Meletios A. Dimopoulos the Greek Myeloma Study Group 《European journal of haematology》2017,99(5):409-414
13.
Clinical features,outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients 下载免费PDF全文
Eirini Katodritou Evangelos Terpos Argiris S. Symeonidis Anastasia Pouli Charikleia Kelaidi Marie‐Christine Kyrtsonis Maria Kotsopoulou Sosana Delimpasi Anna Christoforidou Nikolaos Giannakoulas Nora‐Athina Viniou Ekaterini Stefanoudaki Christina Hadjiaggelidou Dimitrios Christoulas Evgenia Verrou Vassiliki Gastari Sofia Papadaki Genovefa Polychronidou Athina Papadopoulou Evlambia Giannopoulou Efstathios Kastritis Alexandra Kouraklis Pavlina Konstantinidou Achilles Anagnostopoulos Konstantinos Zervas Meletios A. Dimopoulos 《American journal of hematology》2014,89(8):803-808
Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice is local radiotherapy (R/T) ± surgical excision. The role of adjuvant chemotherapy (C/T) or novel agents (NA) is uncertain. Data related to prognostic factors are inconclusive. Herein, we describe the clinical features, survival and prognosis of 97 consecutive patients, 65 with bone SP (SBP), and 32 with extramedullary SP (SEP), diagnosed and treated in 12 Greek Myeloma Centers. Objective response rate (≥PR) and complete response (CR) was 91.8% and 61.9%, respectively, and did not differ between the 2 groups. Overall, 38 patients relapsed or progressed to multiple myeloma (MM). After a median follow‐up of 60 months, 5 and 10‐year overall survival (OS) probability was 92% and 89% in SEP and 86% and 69% in SBP, respectively (P = 0.2). The 5‐ and 10‐year MM‐free survival (MMFS) probability was 90% and 70% for patients with SEP vs. 59% and 50% for patients with SBP, respectively (P = 0.054). Overall, the 5‐ and 10‐year OS probability, plasmacytoma relapse‐free survival (PRFS), progression‐free survival and MMFS was 84% and 78%, 72% and 58%, 58% and 43%, and 70% and 59%, respectively. In the multivariate analysis, prolonged PRFS and young age were positive predictors of OS. Achievement of CR was the only positive predictor of PRFS. Immunoparesis was the only negative predictor of progression to MM. The addition of C/T or NA‐based treatment increased toxicity without offering any survival advantage over R/T. Am. J. Hematol. 89:803–808, 2014. © 2014 Wiley Periodicals, Inc. 相似文献
14.
Ludwig H Avet-Loiseau H Bladé J Boccadoro M Cavenagh J Cavo M Davies F de la Rubia J Delimpasi S Dimopoulos M Drach J Einsele H Facon T Goldschmidt H Hess U Mellqvist UH Moreau P San-Miguel J Sondergeld P Sonneveld P Udvardy M Palumbo A 《The oncologist》2012,17(5):592-606
The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies. 相似文献
15.
16.
Meletios A. Dimopoulos Philippe Moreau Bradley Augustson Nelson Castro Tomas Pika Sosana Delimpasi Javier De la Rubia Angelo Maiolino Tony Reiman Joaquin Martinez-Lopez Thomas Martin Joseph Mikhael Kwee Yong Marie-Laure Risse Gaelle Asset Sylvia Marion Roman Hajek 《American journal of hematology》2023,98(1):E15-E19
17.
Michael Michael Efstathios Kastritis Sossana Delimpassi Evridiki Michalis Panagiotis Repoussis Marie-Christine Kyrtsonis Eirini Katodritou Nicolaos Anagnostopoulos Konstantinos Zervas Meletios A. Dimopoulos 《Clinical Lymphoma, Myeloma & Leukemia》2010,10(1):56-61
Background:Primary systemic light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chain–derived amyloid fibrils in various tissues leading to multiorgan dysfunction.Patients and Methods:In order to define characteristics, treatment, and outcome of Greek patients with AL amyloidosis, we analyzed 112 unselected patients with AL from several hospitals.Results:The heart was involved in 59% of patients and kidneys in 71%. Patients were treated with several different treatment regimens; high-dose dexamethasone-based regimens were used as primary treatment in 43% and melphalan-based regimens in 37%, while 12% received up-front bortezomib with dexamethasone. A hematologic response to first-line therapy was documented in 50% (complete response, 14.5%), and organ responses were observed in 25% of patients, the latter being strongly associated with achievement of hematologic response. Median overall survival was 34.2 months and was independently affected by heart involvement, creatinine, age, involvement of ≥ 2 organs, and bone marrow plasmacytosis > 30%. In patients with cardiac involvement, advanced age and extended bone marrow plasmacytosis were associated with an even worse outcome, while for patients without heart involvement, only bone marrow plasmacytosis was independently associated with survival. Hematologic response was associated with improved survival in patients with heart involvement but mostly in patients with less bone marrow infiltration.Conclusion:In this first series of patients from Greece with AL amyloidosis, disease features and outcome appeared similar to those reported from tertiary centers. Heart involvement and bone marrow plasma cell infiltration comprise adverse prognostic factors but also indicate the heterogeneity of the disease and the need for individual treatment approaches. 相似文献
18.
19.
Kastritis E Terpos E Roussou M Gavriatopoulou M Pamboukas C Boletis I Marinaki S Apostolou T Nikitas N Gkortzolidis G Michalis E Delimpasi S Dimopoulos MA 《Blood》2012,119(23):5384-5390
In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and most had renal and/or cardiac involvement and elevated cardiac biomarkers. Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d were further evaluated in phase 2. On intention to treat, 20 (55%) patients achieved a hematologic response, including 3 (8%) complete remissions. Hematologic responses were seen at all dose levels and in 4 of 5 patients who had received bortezomib previously. An organ response was recorded in 22% of patients on intention-to-treat and in 40% of patients who survived at least 6 months. The median time to progression was 10 months and the 2-year survival was 41%. Fatigue, nonneutropenic infections, and rash were the most common toxicities. The results of the present study show that RdC is an oral regimen with activity in primary systemic light chain amyloidosis and may be an additional treatment option, especially for patients with preserved organ function or for patients who cannot receive or who relapse after bortezomib. This study is registered at www.clinicaltrials.gov as NCT00981708. 相似文献
20.